GlassScriptPhysician profile
Debra L Foley
NPI 1356376339
$4,972.14
in general payments reported to CMS, 2019-2025
26 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,297 · 2022: $1,005 · 2023: $1,172 · 2024: $819 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,670.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $995.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $930.39 | 2021-2025 | Farxiga, Airsupra |
| Abbvie INC. | $763.51 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $398.27 | 2021-2025 | |
| Exact Sciences Corporation | $294.98 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $275.30 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $223.34 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $181.52 | 2021-2025 | |
| Abiomed | $140.04 | 2024 | Impella |
| Glaxosmithkline, LLC. | $138.09 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.22 | 2021-2023 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $77.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $62.47 | 2021-2023 | Xarelto |
| Phadia US INC. | $57.00 | 2022-2023 | Immunocap |
| Biohaven Pharmaceuticals, INC. | $41.18 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $39.35 | 2023 | Gemtesa |
| Corcept Therapeutics | $38.51 | 2024 | Korlym |
| Mannkind Corporation | $38.30 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $30.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.80 | 2024-2025 | Jardiance, Synjardy |
| Nevro Corp. | $29.29 | 2022 | |
| Currax Pharmaceuticals LLC | $26.94 | 2023 | Onzetra Xsail, Contrave |
| Abbott Laboratories | $22.46 | 2021 | |
| Gilead Sciences, INC. | $21.34 | 2025 | |
| Hologic Sales and Service, LLC | $20.19 | 2025 | Aptima, Thinprep 2000 Processor |
| Alvogen INC | $15.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.